Long‐Term Cholesterol‐Lowering Effect of Colestipol Resin in Humans*

Abstract

In a double‐blind study, colestipol resin was administered to hypercholesterolemic patients for periods ranging from one to three years. Twenty‐two patients received colestipol, and 22 placebo; all received the usual American diet. This medical interruption of the enterohepatic circulation of bile acids significantly lowered the concentration of serum cholesterol within a month, and maintained it at that level during the period of study. The effect on the triglyceride level was not so marked, though there was a tendency toward elevation. Side effects from the placebo were similar to those from the drug. This cholesterol‐lowering action of colestipol may be of importance in relation to arteriosclerosis.